Cutera (CUTR) 10-Q 4 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'CUTERA INC	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	14,312,731
Amendment Flag	'false	'
Entity Central Index Key	'0001162461	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Accelerated Filer	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$10,902	$16,242
Marketable investments	70,696	66,831
Accounts receivable, net	7,596	9,679
Inventories	10,030	9,006
Deferred tax asset	32	31
Other current assets and prepaid expenses	1,772	1,507
Total current assets	101,028	103,296
Property and equipment, net	1,329	1,362
Deferred tax asset, net of current portion	342	329
Intangibles, net	1,632	2,019
Goodwill	1,339	1,339
Other long-term assets	15	324
Total assets	105,685	108,669
Current liabilities:	'	'
Accounts payable	2,028	1,820
Accrued liabilities	7,473	9,328
Deferred revenue	8,561	7,494
Total current liabilities	18,062	18,642
Deferred revenue, net of current portion	4,578	4,340
Income tax liability	144	108
Other long-term liabilities	1,141	1,314
Total liabilities	23,925	24,404
Commitments and Contingencies (Note 10)	'	'
Stockholders’ equity:	'	'
Common stock, $0.001 par value; authorized: 50,000,000 shares; issued and outstanding: 14,311,168 and 13,931,833 shares at June 30, 2014 and December 31, 2013, respectively	14	14
Additional paid-in capital	102,649	98,820
Accumulated deficit	-20,971	-14,620
Accumulated other comprehensive income	68	51
Total stockholders’ equity	81,760	84,265
Total liabilities and stockholders’ equity	105,685	108,669
Convertible Preferred Stock [Member]	'	'
Stockholders’ equity:	'	'
Convertible preferred stock, $0.001 par value; authorized: 5,000,000 shares; none issued and outstanding	$0	$0

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, authorized	50,000,000	50,000,000
Common stock, issued	14,311,168	13,931,833
Common stock, outstanding	14,311,168	13,931,833
Convertible Preferred Stock [Member]	'	'
Convertible preferred stock, par value (in Dollars per share)	$0.00	$0.00
Convertible preferred stock, authorized	5,000,000	5,000,000
Convertible preferred stock, issued	0	0
Convertible preferred stock, outstanding	0	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net revenue:	'	'	'	'
Products	$13,171,000	$15,053,000	$24,923,000	$26,576,000
Service	4,553,000	4,507,000	8,990,000	8,951,000
Total net revenue	17,724,000	19,560,000	33,913,000	35,527,000
Cost of revenue:	'	'	'	'
Products	5,917,000	6,151,000	10,994,000	11,573,000
Service	1,931,000	2,291,000	4,157,000	4,286,000
Total cost of revenue	7,848,000	8,442,000	15,151,000	15,859,000
Gross profit	9,876,000	11,118,000	18,762,000	19,668,000
Operating expenses:	'	'	'	'
Sales and marketing	7,754,000	7,170,000	15,085,000	13,626,000
Research and development	2,622,000	2,217,000	5,266,000	4,338,000
General and administrative	2,335,000	2,354,000	4,899,000	4,643,000
Total operating expenses	12,711,000	11,741,000	25,250,000	22,607,000
Loss from operations	-2,835,000	-623,000	-6,488,000	-2,939,000
Interest and other income, net	138,000	75,000	218,000	210,000
Loss before income taxes	-2,697,000	-548,000	-6,270,000	-2,729,000
Provision for income taxes	44,000	90,000	81,000	72,000
Net loss	($2,741,000)	($638,000)	($6,351,000)	($2,801,000)
Net loss per share:	'	'	'	'
Basic and Diluted (in Dollars per share)	($0.19)	($0.04)	($0.45)	($0.19)
Weighted-average number of shares used in per share calculations:	'	'	'	'
Basic and Diluted (in Shares)	14,231	14,723	14,127	14,566

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net loss	($2,741)	($638)	($6,351)	($2,801)
Available-for-sale investments	'	'	'	'
Net change in unrealized gain (loss) on available-for-sale investments	26	-125	28	-121
Less: Reclassification adjustment for gains on investments recognized during the year	-1	0	-1	'
Net change in unrealized gain (loss) on available-for-sale investments	25	-125	27	-121
Tax provision (benefit)	9	-2	10	'
Other comprehensive income (loss), net of tax	16	-123	17	-121
Comprehensive loss	($2,725)	($761)	($6,334)	($2,922)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($6,351)	($2,801)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'
Stock-based compensation	1,318	1,622
Depreciation and amortization	660	646
Other	93	50
Changes in assets and liabilities:	'	'
Accounts receivable	2,079	1,299
Inventories	-1,024	596
Other current assets and prepaid expenses	-99	242
Other long-term assets	309	49
Accounts payable	208	323
Accrued liabilities	-1,885	-1,952
Other long-term liabilities	-141	-112
Deferred revenue	1,305	1,117
Income tax liability	36	-87
Net cash provided by (used in) operating activities	-3,492	992
Cash flows from investing activities:	'	'
Acquisition of property, equipment and software	-283	-306
Proceeds from sales of marketable investments	4,681	4,975
Proceeds from maturities of marketable investments	19,165	16,200
Purchase of marketable investments	-27,850	-37,243
Net cash used in investing activities	-4,287	-16,374
Cash flows from financing activities:	'	'
Proceeds from exercise of stock options and employee stock purchase plan	2,511	3,781
Payments on capital lease obligations	-72	-60
Net cash provided by financing activities	2,439	3,721
Net decrease in cash and cash equivalents	-5,340	-11,661
Cash and cash equivalents at beginning of period	16,242	23,546
Cash and cash equivalents at end of period	$10,902	$11,885

Note_1_Summary_of_Significant_

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	'
	Note 1. Summary of Significant Accounting Policies
	Description of Operations and Principles of Consolidation
	Cutera, Inc. (“Cutera” or the “Company”) is a global provider of laser and other energy-based aesthetic systems for practitioners worldwide. The Company designs, develops, manufactures, and markets laser and other energy-based product platforms for use by physicians and other qualified practitioners which enable them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following key product platforms: CoolGlide, Xeo, Solera, GenesisPlus, Excel V, VariLite, truSculpt and Excel HR. The Company’s products offer multiple hand pieces and applications, which allow customers to upgrade their systems. The sales of systems, upgrades, hand pieces, hand piece refills (Titan and truSculpt) and the distribution of third party manufactured dermal fillers and cosmeceuticals are classified as “Product and upgrade” revenue. In the second quarter of 2014, the Company terminated its agreement with Merz Pharma GmbH’s (“Merz”) for the distribution of its Radiesse® dermal filler product. In addition to Product and upgrade revenue, the Company generates revenue from the sale of post-warranty service contracts, parts, detachable hand piece replacements (except for Titan and truSculpt) and service labor for the repair and maintenance of products that are out of warranty, all of which is classified as “Service revenue.”
	Headquartered in Brisbane, California, the Company has wholly-owned subsidiaries that are currently operational in Australia, Belgium, Canada, France, Japan and Switzerland, that market, sell and service its products outside of the United States. The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated.
	Unaudited Interim Financial Information
	The interim financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December 31, 2013 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (“GAAP”). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s previously filed audited financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission (the “SEC”), on March 18, 2014.
	Use of Estimates
	The preparation of interim Condensed Consolidated Financial Statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported and disclosed in the Condensed Consolidated Financial Statements and the accompanying notes. Actual results could differ materially from those estimates. On an ongoing basis, the Company evaluates these estimates, including those related to warranty obligation, sales commission, accounts receivable and sales allowances, provision for excess and obsolete inventories, fair values of marketable investments, fair values of acquired intangible assets, useful lives of intangible assets and property and equipment, fair value of options to purchase the Company’s stock, recoverability of deferred tax assets, and effective income tax rates, among others. Management bases these estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accountings Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and shall take effective on January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of it is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.

Note_2_Cash_Cash_Equivalents_a

Note 2 - Cash, Cash Equivalents and Marketable Investments	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Cash, Cash Equivalents, and Marketable Securities [Text Block]	'
	Note 2. Cash, Cash Equivalents and Marketable Investments
	The Company invests its cash primarily in money market funds, commercial paper, corporate notes and bonds, municipal bonds, and debt securities issued by the U.S. government and its agencies. The Company considers all highly liquid investments, with an original maturity of three months or less at the time of purchase, to be cash equivalents. Investments with maturities of greater than three months at the time of purchase are accounted for as “available-for-sale,” are carried at fair value with unrealized gains and losses reported as a component of stockholders’ equity, held for use in current operations and classified in current assets as “marketable investments.”
	The following tables summarize the components, and the unrealized gains and losses position, related to the Company’s cash and cash equivalents and marketable investments (in thousands):
	30-Jun-14	Amortized		Gross		Gross			Fair Market
		Cost		Unrealized		Unrealized			Value
				Gains		Losses
	Cash and cash equivalents:
	Cash	$	5,154	$	—	$	—		$	5,154
	Money market funds		2,749		—		—			2,749
	Commercial paper		2,999		—		—			2,999
	Total cash and cash equivalents		10,902		—		—			10,902
	Marketable investments:
	U.S. government notes		17,109		28		—			17,137
	U.S. government agencies		21,040		39		—			21,079
	Municipal securities		3,830		5		(3	)		3,832
	Commercial paper		9,834		4		—			9,838
	Corporate debt securities		18,755		56		(1	)		18,810
	Total marketable investments		70,568		132		(4	)		70,696
	Total cash, cash equivalents and marketable investments	$	81,470	$	132	$	(4	)	$	81,598
	31-Dec-13	Amortized		Gross		Gross			Fair Market
		Cost		Unrealized		Unrealized			Value
				Gains		Losses
	Cash and cash equivalents:
	Cash	$	3,816	$	—	$	—		$	3,816
	Money market funds		9,926		—		—			9,926
	Commercial paper		2,500		—		—			2,500
	Total cash and cash equivalents		16,242		—		—			16,242
	Marketable investments:
	U.S. government notes		10,516		11		(5	)		10,522
	U.S. government agencies		25,823		38		(3	)		25,858
	Municipal securities		2,043		1		(5	)		2,039
	Commercial paper		10,239		3		—			10,242
	Corporate debt securities		18,109		61		—			18,170
	Total marketable investments		66,730		114		(13	)		66,831
	Total cash, cash equivalents and marketable investments	$	82,972	$	114	$	(13	)	$	83,073
	As of June 30, 2014 and December 31, 2013, the total gross unrealized losses were $4,000 and $13,000, respectively, and were related to interest rate changes on available-for-sale marketable investments. The Company has concluded that it is more-likely-than-not that the securities will be held until maturity or the recovery of their cost basis. No securities were in unrealized loss positions for more than 12 months.
	The following table summarizes the contractual maturities of the Company’s available-for-sale securities, classified as marketable investments as of June 30, 2014 (in thousands):
		Amount
	Due in less than one year	$	33,828
	Due in 1 to 3 years		36,868
		$	70,696

Note_3_Fair_Value_of_Financial

Note 3 - Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 3. Fair Value of Financial Instruments
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
		●	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.
		●	Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.
		●	Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions.
	In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.
	As of June 30, 2014, financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands):
	30-Jun-14		Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds		$	2,749	$	—	$	—	$	2,749
	Commercial paper			—		2,999		—		2,999
	Marketable investments:
	Available-for-sale securities			—		70,696		—		70,696
	Total assets at fair value		$	2,749	$	73,695	$	—	$	76,444
	As of December 31, 2013, financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above was as follows (in thousands):
	31-Dec-13		Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds		$	9,926	$	—	$	—	$	9,926
	Commercial paper			—		2,500		—		2,500
	Marketable investments:
	Available-for-sale securities			—		66,831		—		66,831
	Total assets at fair value		$	9,926	$	69,331	$	—	$	79,257
	The Company’s Level 2 investments include U.S. government-backed securities and corporate securities that are valued based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. The average remaining maturity of the Company’s Level 2 investments as of June 30, 2014 is less than 36 months and all of these investments are rated by S&P and Moody’s at A or better.

Note_4_Inventories

Note 4 - Inventories	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 4. Inventories
	As of June 30, 2014 and December 31, 2013, inventories consist of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Raw materials	$	6,296	$	5,989
	Finished goods		3,734		3,017
	Total	$	10,030	$	9,006

Note_5_Warranty

Note 5 - Warranty	6 Months Ended
	Jun. 30, 2014
Product Warranties Disclosures [Abstract]	'
Product Warranty Disclosure [Text Block]	'
	Note 5. Warranty
	The Company provides a standard one-year warranty on all systems. Warranty coverage provided is for labor and parts necessary to repair the systems during the warranty period. The Company accounts for the estimated warranty cost of the standard warranty coverage as a charge to costs of revenue when revenue is recognized. The estimated warranty cost is based on historical product performance. To determine the estimated warranty reserve, the Company utilizes historical service costs to calculate the expected service expense per system and applies this to the equivalent number of units exposed under warranty. The Company updates these estimated charges every quarter.
	The following table provides the changes in the product warranty accrual for the three and six months ended June 30, 2014 and 2013 (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Beginning Balance	$	1,071		$	1,059		$	1,202		$	1,212
	Add: Accruals for warranties issued during the period		591			811			1,047			1,712
	Less: Settlements made during the period		(582	)		(821	)		(1,169	)		(1,875	)
	Ending Balance	$	1,080		$	1,049		$	1,080		$	1,049

Note_6_Deferred_Service_Contra

Note 6 - Deferred Service Contract Revenue	6 Months Ended
	Jun. 30, 2014
Deferred Revenue Disclosure [Abstract]	'
Deferred Revenue Disclosure [Text Block]	'
	Note 6. Deferred Service Contract Revenue
	The Company generates Service revenue from the sale of extended service contracts and from time and material services provided to customers who are not under a warranty or extended service contract. Service contract revenue is recognized on a straight-line basis over the period of the applicable contract. Service revenue, from customers whose systems are not under a service contract, is recognized as the services are provided.
	The following table provides changes in the deferred service contract revenue balance for the three and six months ended June 30, 2014 and 2013 (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Beginning Balance	$	12,292		$	9,151		$	11,637		$	8,539
	Add: Payments received		3,856			3,538			7,567			7,140
	Less: Revenue recognized		(3,147	)		(2,974	)		(6,203	)		(5,964	)
	Ending Balance	$	13,001		$	9,715		$	13,001		$	9,715
	Costs for extended service contracts were $1.8 million and $3.5 million for both the three and six months ended June 30, 2014 and 2013, respectively.

Note_7_Stockholders_Equity_and

Note 7 - Stockholders' Equity and Stock-based Compensation Expense	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 7. Stockholders’ Equity and Stock-based Compensation Expense
	Stock-based Compensation Expense
	Stock-based compensation expense by department recognized during the three and six months ended June 30, 2014 and 2013 were as follows (in thousands):
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Cost of revenue	$	139	$	166	$	271	$	325
	Sales and marketing		148		198		219		397
	Research and development		115		89		239		190
	General and administrative		291		349		589		710
	Total stock-based compensation expense	$	693	$	802	$	1,318	$	1,622
	Under the 2004 Equity Incentive Plan, as amended, the Company issued 291,089 shares of common stock during the six months ended June 30, 2014, in conjunction with stock options exercised.
	During the six months ended June 30, 2014, the following number of equity awards of the Company’s common stock was granted (in thousands):
		Shares
	Stock options		177
	Restricted stock units		49
	Total		226
	As of June 30, 2014, there was $3.5 million of unrecognized compensation expense, net of projected forfeitures, related to non-vested stock awards. The expense is expected to be recognized over the remaining weighted-average period of 2.3 years.

Note_8_Net_Loss_Per_Share

Note 8 - Net Loss Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 8. Net Loss Per Share
	Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted net loss per common share is the same as basic net loss per common share, as the effect of the potential common stock equivalents is anti-dilutive and as such is excluded from the calculations of the diluted net loss per share.
	The following numbers of shares outstanding, prior to the application of the treasury stock method, were excluded from the computation of diluted net loss per common share for the periods presented because including them would have had an anti-dilutive effect (in thousands):
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Options to purchase common stock		3,414		3,519		3,553		3,628
	Restricted stock units		149		140		161		144
	Performance stock units		6		34		6		34
	Employee stock purchase plan shares		54		60		54		60
	Total		3,623		3,753		3,774		3,866

Note_9_Income_Taxes

Note 9 - Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 9. Income Taxes
	The Company’s quarterly income taxes reflect an estimate of the corresponding year’s annual effective tax rate and include, when applicable, adjustments from discrete tax items. For the three and six months ended June 30, 2014, the Company’s tax provision was $44,000 and $81,000, compared to $90,000 and $72,000 for the three and six months ended June 30, 2013. The Company’s income tax provision for the three and six month ended June 30, 2014 and 2013 primarily related to income taxes for the Company’s non-U.S. operations as the Company’s U.S. operations were in a loss position and it maintains a 100% valuation allowance for its U.S. deferred tax assets.
	The Company utilizes the asset and liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. As of June 30, 2014 and December 31, 2013, the Company had a 100% valuation allowance against its U.S. deferred tax assets. Significant management judgment is required in determining any valuation allowance recorded against deferred tax assets. In evaluating the ability to recover deferred tax assets, the Company considered available positive and negative evidence giving greater weight to its recent cumulative losses and its ability to carry-back losses against prior taxable income and lesser weight to its projected financial results due to the challenges of forecasting future periods. The Company also considered, commensurate with its objective verifiability, the forecast of future taxable income including the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies.

Note_10_Commitments_and_Contin

Note 10 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 10. Commitments and Contingencies
	Litigation and Litigation Settlements
	The Company is named from time to time as a party to product liability and contractual lawsuits in the normal course of business. The Company routinely assesses the likelihood of any adverse judgments or outcomes related to legal matters and claims, as well as ranges of probable losses. A determination of the amount of the reserves required, if any, for these contingencies is made after analysis of each known issue, historical experience, whether it is more likely than not that the Company shall incur a loss, and whether the loss is estimable. As of June 30, 2014 and December 31, 2013, the Company was not subject to any material litigation.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	'
	Description of Operations and Principles of Consolidation
	Cutera, Inc. (“Cutera” or the “Company”) is a global provider of laser and other energy-based aesthetic systems for practitioners worldwide. The Company designs, develops, manufactures, and markets laser and other energy-based product platforms for use by physicians and other qualified practitioners which enable them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following key product platforms: CoolGlide, Xeo, Solera, GenesisPlus, Excel V, VariLite, truSculpt and Excel HR. The Company’s products offer multiple hand pieces and applications, which allow customers to upgrade their systems. The sales of systems, upgrades, hand pieces, hand piece refills (Titan and truSculpt) and the distribution of third party manufactured dermal fillers and cosmeceuticals are classified as “Product and upgrade” revenue. In the second quarter of 2014, the Company terminated its agreement with Merz Pharma GmbH’s (“Merz”) for the distribution of its Radiesse® dermal filler product. In addition to Product and upgrade revenue, the Company generates revenue from the sale of post-warranty service contracts, parts, detachable hand piece replacements (except for Titan and truSculpt) and service labor for the repair and maintenance of products that are out of warranty, all of which is classified as “Service revenue.”
	Headquartered in Brisbane, California, the Company has wholly-owned subsidiaries that are currently operational in Australia, Belgium, Canada, France, Japan and Switzerland, that market, sell and service its products outside of the United States. The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated.
Unaudited Interim Financial Information [Policy Text Block]	'
	Unaudited Interim Financial Information
	The interim financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December 31, 2013 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (“GAAP”). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s previously filed audited financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission (the “SEC”), on March 18, 2014.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of interim Condensed Consolidated Financial Statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported and disclosed in the Condensed Consolidated Financial Statements and the accompanying notes. Actual results could differ materially from those estimates. On an ongoing basis, the Company evaluates these estimates, including those related to warranty obligation, sales commission, accounts receivable and sales allowances, provision for excess and obsolete inventories, fair values of marketable investments, fair values of acquired intangible assets, useful lives of intangible assets and property and equipment, fair value of options to purchase the Company’s stock, recoverability of deferred tax assets, and effective income tax rates, among others. Management bases these estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accountings Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and shall take effective on January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of it is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.

Note_2_Cash_Cash_Equivalents_a1

Note 2 - Cash, Cash Equivalents and Marketable Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Unrealized Gain (Loss) on Investments [Table Text Block]	'
	30-Jun-14	Amortized		Gross		Gross			Fair Market
		Cost		Unrealized		Unrealized			Value
				Gains		Losses
	Cash and cash equivalents:
	Cash	$	5,154	$	—	$	—		$	5,154
	Money market funds		2,749		—		—			2,749
	Commercial paper		2,999		—		—			2,999
	Total cash and cash equivalents		10,902		—		—			10,902
	Marketable investments:
	U.S. government notes		17,109		28		—			17,137
	U.S. government agencies		21,040		39		—			21,079
	Municipal securities		3,830		5		(3	)		3,832
	Commercial paper		9,834		4		—			9,838
	Corporate debt securities		18,755		56		(1	)		18,810
	Total marketable investments		70,568		132		(4	)		70,696
	Total cash, cash equivalents and marketable investments	$	81,470	$	132	$	(4	)	$	81,598
	31-Dec-13	Amortized		Gross		Gross			Fair Market
		Cost		Unrealized		Unrealized			Value
				Gains		Losses
	Cash and cash equivalents:
	Cash	$	3,816	$	—	$	—		$	3,816
	Money market funds		9,926		—		—			9,926
	Commercial paper		2,500		—		—			2,500
	Total cash and cash equivalents		16,242		—		—			16,242
	Marketable investments:
	U.S. government notes		10,516		11		(5	)		10,522
	U.S. government agencies		25,823		38		(3	)		25,858
	Municipal securities		2,043		1		(5	)		2,039
	Commercial paper		10,239		3		—			10,242
	Corporate debt securities		18,109		61		—			18,170
	Total marketable investments		66,730		114		(13	)		66,831
	Total cash, cash equivalents and marketable investments	$	82,972	$	114	$	(13	)	$	83,073
Investments Classified by Contractual Maturity Date [Table Text Block]	'
		Amount
	Due in less than one year	$	33,828
	Due in 1 to 3 years		36,868
		$	70,696

Note_3_Fair_Value_of_Financial1

Note 3 - Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	'
	30-Jun-14	Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	2,749	$	—	$	—	$	2,749
	Commercial paper		—		2,999		—		2,999
	Marketable investments:
	Available-for-sale securities		—		70,696		—		70,696
	Total assets at fair value	$	2,749	$	73,695	$	—	$	76,444
	31-Dec-13	Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	9,926	$	—	$	—	$	9,926
	Commercial paper		—		2,500		—		2,500
	Marketable investments:
	Available-for-sale securities		—		66,831		—		66,831
	Total assets at fair value	$	9,926	$	69,331	$	—	$	79,257

Note_4_Inventories_Tables

Note 4 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		June 30,		December 31,
		2014		2013
	Raw materials	$	6,296	$	5,989
	Finished goods		3,734		3,017
	Total	$	10,030	$	9,006

Note_5_Warranty_Tables

Note 5 - Warranty (Tables)	6 Months Ended
	Jun. 30, 2014
Product Warranties Disclosures [Abstract]	'
Schedule of Product Warranty Liability [Table Text Block]	'
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Beginning Balance	$	1,071		$	1,059		$	1,202		$	1,212
	Add: Accruals for warranties issued during the period		591			811			1,047			1,712
	Less: Settlements made during the period		(582	)		(821	)		(1,169	)		(1,875	)
	Ending Balance	$	1,080		$	1,049		$	1,080		$	1,049

Note_6_Deferred_Service_Contra1

Note 6 - Deferred Service Contract Revenue (Tables)	6 Months Ended
	Jun. 30, 2014
Deferred Revenue Disclosure [Abstract]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Beginning Balance	$	12,292		$	9,151		$	11,637		$	8,539
	Add: Payments received		3,856			3,538			7,567			7,140
	Less: Revenue recognized		(3,147	)		(2,974	)		(6,203	)		(5,964	)
	Ending Balance	$	13,001		$	9,715		$	13,001		$	9,715

Note_7_Stockholders_Equity_and1

Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Cost of revenue	$	139	$	166	$	271	$	325
	Sales and marketing		148		198		219		397
	Research and development		115		89		239		190
	General and administrative		291		349		589		710
	Total stock-based compensation expense	$	693	$	802	$	1,318	$	1,622
Schedule of Equity Awards Granted [Table Text Block]	'
		Shares
	Stock options		177
	Restricted stock units		49
	Total		226

Note_8_Net_Loss_Per_Share_Tabl

Note 8 - Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Options to purchase common stock		3,414		3,519		3,553		3,628
	Restricted stock units		149		140		161		144
	Performance stock units		6		34		6		34
	Employee stock purchase plan shares		54		60		54		60
	Total		3,623		3,753		3,774		3,866

Note_2_Cash_Cash_Equivalents_a2

Note 2 - Cash, Cash Equivalents and Marketable Investments (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'	'
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	$4,000	$13,000

Note_2_Cash_Cash_Equivalents_a3

Note 2 - Cash, Cash Equivalents and Marketable Investments (Details) - Unrealized Gains and Losses Related to Marketable Investments (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Cash and cash equivalents:	'	'	'	'
Cash and cash equivalents Amortized Cost	$10,902,000	$16,242,000	$11,885,000	$23,546,000
Cash and cash equivalents Fair Market Value	10,902,000	16,242,000	'	'
Marketable investments:	'	'	'	'
Marketable Investments Amortized Cost	70,568,000	66,730,000	'	'
Gross Unrealized Gains	132,000	114,000	'	'
Gross Unrealized Losses	-4,000	-13,000	'	'
Marketable Investments Fair Market Value	70,696,000	66,831,000	'	'
Cash and cash equivalents and Marketable Investments Amortized Cost	81,470,000	82,972,000	'	'
Gross Unrealized Gains	132,000	114,000	'	'
Gross Unrealized Losses	-4,000	-13,000	'	'
Cash and cash equivalents and Marketable Investments Fair Market Value	81,598,000	83,073,000	'	'
US Treasury and Government [Member]	'	'	'	'
Marketable investments:	'	'	'	'
Marketable Investments Amortized Cost	17,109,000	10,516,000	'	'
Gross Unrealized Gains	28,000	11,000	'	'
Gross Unrealized Losses	'	-5,000	'	'
Marketable Investments Fair Market Value	17,137,000	10,522,000	'	'
Gross Unrealized Gains	28,000	11,000	'	'
Gross Unrealized Losses	'	-5,000	'	'
US Government Agencies Debt Securities [Member]	'	'	'	'
Marketable investments:	'	'	'	'
Marketable Investments Amortized Cost	21,040,000	25,823,000	'	'
Gross Unrealized Gains	39,000	38,000	'	'
Gross Unrealized Losses	'	-3,000	'	'
Marketable Investments Fair Market Value	21,079,000	25,858,000	'	'
Gross Unrealized Gains	39,000	38,000	'	'
Gross Unrealized Losses	'	-3,000	'	'
US States and Political Subdivisions Debt Securities [Member]	'	'	'	'
Marketable investments:	'	'	'	'
Marketable Investments Amortized Cost	3,830,000	2,043,000	'	'
Gross Unrealized Gains	5,000	1,000	'	'
Gross Unrealized Losses	-3,000	-5,000	'	'
Marketable Investments Fair Market Value	3,832,000	2,039,000	'	'
Gross Unrealized Gains	5,000	1,000	'	'
Gross Unrealized Losses	-3,000	-5,000	'	'
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]	'	'	'	'
Marketable investments:	'	'	'	'
Marketable Investments Amortized Cost	9,834,000	10,239,000	'	'
Gross Unrealized Gains	4,000	3,000	'	'
Marketable Investments Fair Market Value	9,838,000	10,242,000	'	'
Gross Unrealized Gains	4,000	3,000	'	'
Corporate Debt Securities [Member]	'	'	'	'
Marketable investments:	'	'	'	'
Marketable Investments Amortized Cost	18,755,000	18,109,000	'	'
Gross Unrealized Gains	56,000	61,000	'	'
Gross Unrealized Losses	-1,000	'	'	'
Marketable Investments Fair Market Value	18,810,000	18,170,000	'	'
Gross Unrealized Gains	56,000	61,000	'	'
Gross Unrealized Losses	-1,000	'	'	'
Cash [Member]	'	'	'	'
Cash and cash equivalents:	'	'	'	'
Cash and cash equivalents Amortized Cost	5,154,000	3,816,000	'	'
Cash and cash equivalents Fair Market Value	5,154,000	3,816,000	'	'
Money Market Funds [Member]	'	'	'	'
Cash and cash equivalents:	'	'	'	'
Cash and cash equivalents Amortized Cost	2,749,000	9,926,000	'	'
Cash and cash equivalents Fair Market Value	2,749,000	9,926,000	'	'
Commercial Paper [Member]	'	'	'	'
Cash and cash equivalents:	'	'	'	'
Cash and cash equivalents Amortized Cost	2,999,000	2,500,000	'	'
Cash and cash equivalents Fair Market Value	$2,999,000	$2,500,000	'	'

Note_2_Cash_Cash_Equivalents_a4

Note 2 - Cash, Cash Equivalents and Marketable Investments (Details) - Maturities of Available-for-Sale Securities (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Maturities of Available-for-Sale Securities [Abstract]	'	'
Due in less than one year	$33,828	'
Due in 1 to 3 years	36,868	'
	$70,696	$66,831

Note_3_Fair_Value_of_Financial2

Note 3 - Fair Value of Financial Instruments (Details)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Maximum Maturity Period of Investments	'36 years

Note_3_Fair_Value_of_Financial3

Note 3 - Fair Value of Financial Instruments (Details) - Summary of Fair Value of Financial Instruments (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	$10,902	$16,242
Available-for-sale securities	70,696	66,831
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets at fair value	2,749	9,926
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	2,749	9,926
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	70,696	66,831
Total assets at fair value	73,695	69,331
Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	2,999	2,500
Fair Value, Measurements, Recurring [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	70,696	66,831
Total assets at fair value	76,444	79,257
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	2,749	9,926
Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	2,749	9,926
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	2,999	2,500
Commercial Paper [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	$2,999	$2,500

Note_4_Inventories_Details_Sum

Note 4 - Inventories (Details) - Summary of Inventories (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of Inventories [Abstract]	'	'
Raw materials	$6,296	$5,989
Finished goods	3,734	3,017
Total	$10,030	$9,006

Note_5_Warranty_Details

Note 5 - Warranty (Details)	6 Months Ended
	Jun. 30, 2014
Product Warranties Disclosures [Abstract]	'
Period of Warranty	'1 year

Note_5_Warranty_Details_Summar

Note 5 - Warranty (Details) - Summary of Warranties (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Summary of Warranties [Abstract]	'	'	'	'
Beginning Balance	$1,071	$1,059	$1,202	$1,212
Add: Accruals for warranties issued during the period	591	811	1,047	1,712
Less: Settlements made during the period	-582	-821	-1,169	-1,875
Ending Balance	$1,080	$1,049	$1,080	$1,049

Note_6_Deferred_Service_Contra2

Note 6 - Deferred Service Contract Revenue (Details) (USD $)	3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
			Nonsoftware Service, Support and Maintenance Arrangement [Member]	Nonsoftware Service, Support and Maintenance Arrangement [Member]
Note 6 - Deferred Service Contract Revenue (Details) [Line Items]	'	'	'	'
Deferred Revenue, Costs Incurred	$1.80	$3.50	$1.80	$3.50

Note_6_Deferred_Service_Contra3

Note 6 - Deferred Service Contract Revenue (Details) - Summary of Deferred Service Contract Revenue (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Summary of Deferred Service Contract Revenue [Abstract]	'	'	'	'
Beginning Balance	$12,292	$9,151	$11,637	$8,539
Add: Payments received	3,856	3,538	7,567	7,140
Less: Revenue recognized	-3,147	-2,974	-6,203	-5,964
Ending Balance	$13,001	$9,715	$13,001	$9,715

Note_7_Stockholders_Equity_and2

Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details) (USD $)	6 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	291,089
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$3.50
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'2 years 109 days

Note_7_Stockholders_Equity_and3

Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details) - Stock-based Compensation Expense by Department (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Stock-based compensation expense	$693	$802	$1,318	$1,622
Cost of Sales [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Stock-based compensation expense	139	166	271	325
Selling and Marketing Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Stock-based compensation expense	148	198	219	397
Research and Development Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Stock-based compensation expense	115	89	239	190
General and Administrative Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Stock-based compensation expense	$291	$349	$589	$710

Note_7_Stockholders_Equity_and4

Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details) - Summary of Equity Awards Granted	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details) - Summary of Equity Awards Granted [Line Items]	'
Stock options	177
Total	226
Restricted Stock Units (RSUs) [Member]	'
Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details) - Summary of Equity Awards Granted [Line Items]	'
Restricted stock units	49

Note_8_Net_Loss_Per_Share_Deta

Note 8 - Net Loss Per Share (Details) - Antidilutive Securities Excluded from Computation of Earnings Per Share	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of diluted net loss per common share	3,623	3,753	3,774	3,866
Equity Option [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of diluted net loss per common share	3,414	3,519	3,553	3,628
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of diluted net loss per common share	149	140	161	144
Performance Shares [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of diluted net loss per common share	6	34	6	34
Equity Unit Purchase Agreements [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of diluted net loss per common share	54	60	54	60

Note_9_Income_Taxes_Details

Note 9 - Income Taxes (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'	'	'	'
Income Tax Expense (Benefit)	$44,000	$90,000	$81,000	$72,000	'
DeferredTaxAssetsValuationAllowancePercentage	'	'	100.00%	'	100.00%